Whole Body MRI for Li-Fraumeni Syndrome

Dana Farber Cancer Institute, Boston, MA
Li-Fraumeni SyndromeWhole Body MRI - Device
Any Age
All Sexes

Study Summary

This trial is testing if MRI can be used to screen for cancer in people with LFS and other cancer predisposition syndromes.

Eligible Conditions
  • Li-Fraumeni Syndrome

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 4 years

3 years
Detection of prevalent and incident cancers on WB-MRI in pediatric and adult patients with Li Fraumeni and other inherited cancer predisposition syndromes.
Malignant Neoplasms
4 years
Radionuclide Imaging
Return of pediatric and adult patients with other cancer predisposition syndromes year-after-year for 4 annual scans.

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Whole Body MRI
1 of 1

Experimental Treatment

150 Total Participants · 1 Treatment Group

Primary Treatment: Whole Body MRI · No Placebo Group · N/A

Whole Body MRI
Experimental Group · 1 Intervention: Whole Body MRI · Intervention Types: Device
First Studied
Drug Approval Stage
How many patients have taken this drug
Whole Body MRI

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,029 Previous Clinical Trials
755,685 Total Patients Enrolled
1 Trials studying Li-Fraumeni Syndrome
1,500 Patients Enrolled for Li-Fraumeni Syndrome
Allison O'Neill, MDPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
2 Previous Clinical Trials
18 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a genetic or hereditary condition that increases your risk for certain types of cancer. This includes Li Fraumeni Syndrome, Hereditary Retinoblastoma, Hereditary Paraganglioma/Pheochromocytoma Syndrome, Multiple Endocrine Neoplasia, Opsoclonus-Myoclonus Syndrome, Familial Neuroblastoma, Rapid-Onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD syndrome), Congenital Central Hypoventilation Syndrome (CCHS), Von Hippel-Lindau Syndrome, or other rare cancer predisposition syndromes.
Participants must be adults and not children.
You have a rare genetic condition that increases your risk of developing cancer, such as Li Fraumeni Syndrome or other inherited cancer predisposition syndromes.
You must be 18 years of age or older.